To elucidate the underlying mechanisms of low response rates to PD‐1 blockade and lenvatinib therapy in HCC, we scrutinized the tumor immune landscape.​ The expression profiles of three gene sets with different immune functions, that is, co‐stimulatory, cytotoxic/effector, and co‐inhibitory/exhaustion, were evaluated. This evidence concerns the gene PDCD1 and neoplasm.